Clinical Trials
2 trialsNCT06202066 2026-05-28
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT02334865 2026-05-15
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
Phase 1 Active not recruiting